Your Strongest Ally to Conquer Cancer

Phone: 505.842.8171

dotAfter Hours: 505.857.3877

dotPharmacy: 505.822.3911




Latest Cancer News

Rituxan Improves Survival in Young Adults with Acute Lymphoblastic Leukemia (09-26-2016)

Acccording to results recently published in the New England Journal of Medicine, young adults with CD20-positive, Philadelphia chromosome  (PH)-negative acute lymphoblastic leukemia (ALL), experience survival benefits with the addition of Rituxan® (rituximab)... Continue Reading

CDC Vaccine Information and Recommendations for the 2016/17 Influenza Season (09-22-2016)

With the start of a new school year and the approaching winter, it’s time to get informed about the most critical information regarding the 2016/17 influenza vaccines and CDC’s vaccination recommendations. The CDC recommends that everyone aged 6... Continue Reading

Cotellic®/Zelboraf® Combo: New Standard of Care for Melanoma (09-20-2016)

The treatment combination consisting of Cotellic® (cobimetinib) plus Zelboraf® (vemurafenib) improves overall survival for patients with advanced, BRAF (V600) mutation-positive melanoma. These confirmatory results have led to this treatment combination... Continue Reading

FDA Grants Breakthrough Therapy Designation to Keytruda® for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (09-14-2016)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Keytruda® (pembrolizumab) for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). The FDA’s Breakthrough Therapy Designation... Continue Reading

Whole-Brain Radiotherapy Fails to Benefit Most Patients with Lung Cancer (09-13-2016)

Whole-brain radiotherapy (WBRT) provides “little additional clinically significant benefit” for patients with non–small cell lung cancer (NSCLC) with brain metastases, according to doctors performing the first large-scale randomized controlled... Continue Reading

Keytruda® Approved for Advanced Head and Neck Cancer (09-7-2016)

The United States Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) for the treatment of advanced head and neck cancer that has stopped responding to platinum-based chemotherapy agents.1 Globally, head and neck cancer comprises... Continue Reading

MammaPrint Might Help Identify Breast Cancer Patients Who Could Safely Opt Out of Chemo (09-7-2016)

MammaPrint, a 70-gene signature test, might help healthcare providers and patients determine whether they will derive a benefit from chemotherapy, or if they could safely choose to not receive chemotherapy for early-stage breast cancer. These results... Continue Reading

FDA Accepts Priority Review of Rucaparib For The Treatment Of Advanced Mutant BRCA Ovarian Cancer (09-6-2016)

The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for accelerated approval of rucaparib and granted priority review status to the application for the treatment of advanced ovarian cancer in patients with deleterious... Continue Reading

Inotuzumab Ozogamicin Improves Progression-Free Survival in Acute Leukemia (09-6-2016)

The investigative agent, inotuzumab ozogamicin, significantly improves progression-free survival and 2-year survival rates among patients with acute lymphoblastic leukemia that has stopped responding to prior therapy. These results were recently published... Continue Reading

ASCO Treatment Recommendations for HR+, Metastatic Breast Cancer (09-5-2016)

The American Society of Clinical Oncology (ASCO) recently convened an Expert Panel to create recommendations for endocrine therapy for women with hormone-receptor (HR)-positive, metastatic breast cancer. The panel conducted “a systematic review of evidence... Continue Reading

Revlimid® Reduces Need for Blood Transfusions in Some Myelodysplastic Syndromes (08-31-2016)

The agent Revlimid (lenalidomide) reduces the need for blood transfusions among patients with lower-risk, non-del (5q) myelodysplastic syndromes who are dependent upon red blood cell transfusions, but are not eligible for erythropoiesis-stimulating agents.... Continue Reading

SGO, ASCO Issue New Guidelines for Ovarian Cancer Treatment (08-22-2016)

A new joint clinical practice guideline from the American Society of Clinical Oncology (ASCO) and the Society of Gynecologic Oncology (SGO) states that neoadjuvant chemotherapy (NACT) is the optimal first-line treatment for some women who have newly diagnosed... Continue Reading

Next Page »